Prøve GULL - Gratis
Where AR & VR Are Headed In Life Sciences Industry?
BioSpectrum Asia
|March 2020
The rise of MedTech is transforming the healthcare industry, as augmented reality (AR) and virtual reality (VR) have pushed the right buttons with players by offering high-tech solutions to fix prevailing challenges in medical training, diagnostics, and treatments. The development of state-of-the-art technologies such as digital reality has disrupted the industrial scenario, and tools such as AR and VR have gained immense popularity in one stroke. Yet, the industrial adoption of digital reality remained significantly low since its inception, and the application range was fairly narrow due to low penetration and high cost of AR and VR tools.
-
The unprecedented growth of the electronics and telecommunications industry marks this decade as the golden period for advancements in technology. Next-generation technologies have given modern electronic appliances advanced processing controls, which enable end-users to experience the new aspects of the real world.
Hearteningly, though, the technology has witnessed widespread implementation in the recent years. In 2017, the global market for virtual reality accounted for nearly $ 3 billion, and the valuation is set to grow at least twice as large by 2022. Now, augmented reality (AR) and virtual reality (VR) tools are taking over efficiency- and testing-related tasks in a widening range of industrial applications.
Seeing is believing’
Despite the advent of many groundbreaking inventions and medical discoveries, the healthcare industry is still grappling to find a cure for many deadly diseases. As there is no loss costlier than the loss of a human life, healthcare industry has begun to invest in AR and VR driven simulation tools to discover new and efficient ways to save more lives.
Healthcare industry is one of the very first and very few industries to embrace digital reality on a significantly large scale. In 2018, the adoption of medical devices integrated with AR and VR technologies in the healthcare industry generated a revenue of $ 600 million. Taking into consideration the rate at which the penetration of digital reality is increasing in this landscape, the global market for AR and VR in healthcare is expected to reach a valuation of more than $ 15 billion by 2026. The healthcare AR and VR market is set to witness unprecedented growth at an astonishing CAGR (compound annual growth rate) of nearly 49 per cent between 2018 and 2026.
Denne historien er fra March 2020-utgaven av BioSpectrum Asia.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA BioSpectrum Asia
BioSpectrum Asia
Waters launches charge detection mass spectrometry technology
US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia
The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
WHO strengthens coordination for NTD programmes and supply chain delivery
The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
All-in-one coronavirus vaccines to save millions in future pandemics
A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
NTU in Singapore introduces Master of Science course in Chinese Medicine
From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
ProSpecBio launches Activin-A recombinant protein for brain injury research
Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
PAHO publishes guide for designing AI instructions in public health
The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Prerna launches India's first MicroRNA based blood test for breast cancer screening
Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan
Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.
1 min
BioSpectrum Asia Nov 2025
Translate
Change font size

